MAP2K7 and cancer: Previous in vitro and in vivo studies in immune-compromised mice demonstrated that SOS1i reduced the formation of GTP-loaded RAS, limited cellular proliferation of human tumors driven by various KRAS mutations, and enhanced MEK inhibition in KRAS-dependent cancers (23).